Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Understanding of safety monitoring in clinical trials by individuals with CF or their parents: A qualitative analysis.

Kern-Goldberger AS, Hessels AJ, Saiman L, Quittell LM.

J Cyst Fibros. 2018 Mar 14. pii: S1569-1993(18)30014-6. doi: 10.1016/j.jcf.2018.01.011. [Epub ahead of print]

PMID:
29550263
2.

Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results.

Lechtzin N, Mayer-Hamblett N, West NE, Allgood S, Wilhelm E, Khan U, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Gibson RL, Orenstein D, Milla C, Clancy JP, Antony V, Goss CH; eICE Study Team.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1144-1151. doi: 10.1164/rccm.201610-2172OC.

PMID:
28608719
3.

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.

Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2016 Feb;169:116-21.e2. doi: 10.1016/j.jpeds.2015.08.042. Epub 2015 Sep 19. Erratum in: J Pediatr. 2018 Jun;197:322.

PMID:
26388208
4.

Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening.

Kay DM, Langfelder-Schwind E, DeCelie-Germana J, Sharp JK, Maloney B, Tavakoli NP, Saavedra-Matiz CA, Krein LM, Caggana M, Kier C; New York State Cystic Fibrosis Newborn Screening Consortium.

Pediatr Pulmonol. 2015 Aug;50(8):771-80. doi: 10.1002/ppul.23222. Epub 2015 Jun 22.

PMID:
26098992
5.

Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis.

Muhlebach MS, Heltshe SL, Popowitch EB, Miller MB, Thompson V, Kloster M, Ferkol T, Hoover WC, Schechter MS, Saiman L; STAR-CF Study Team.

Ann Am Thorac Soc. 2015 Jun;12(6):864-71. doi: 10.1513/AnnalsATS.201412-596OC.

6.

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.

Tiddens HA, De Boeck K, Clancy JP, Fayon M, H G M A, Bresnik M, Derchak A, Lewis SA, Oermann CM; ALPINE study investigators.

J Cyst Fibros. 2015 Jan;14(1):111-9. doi: 10.1016/j.jcf.2014.06.003. Epub 2014 Aug 1.

7.

Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators.

Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2.

8.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27.

9.

Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.

Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD; ISIS Study Group.

JAMA. 2012 Jun 6;307(21):2269-77. doi: 10.1001/jama.2012.5214.

10.

Infection control knowledge, attitudes, and practices among cystic fibrosis patients and their families.

Miroballi Y, Garber E, Jia H, Zhou JJ, Alba L, Quittell LM, Angst D, Cabana M, Saiman L; CF Infection Control Study Consortium.

Pediatr Pulmonol. 2012 Feb;47(2):144-52. doi: 10.1002/ppul.21528. Epub 2011 Aug 24.

PMID:
22241572
11.

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators.

Pediatr Pulmonol. 2012 Feb;47(2):125-34. doi: 10.1002/ppul.21525. Epub 2011 Aug 9.

12.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2011 Nov;159(5):819-824.e1. doi: 10.1016/j.jpeds.2011.05.005. Epub 2011 Jun 25.

13.

Adherence with tobramycin inhaled solution and health care utilization.

Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM.

BMC Pulm Med. 2011 Jan 20;11:5. doi: 10.1186/1471-2466-11-5.

14.

Facial palsy and idiopathic intracranial hypertension in twins with cystic fibrosis and hypovitaminosis A.

Obeid M, Price J, Sun L, Scantlebury MH, Overby P, Sidhu R, Chiriboga CA, Quittell LM.

Pediatr Neurol. 2011 Feb;44(2):150-2. doi: 10.1016/j.pediatrneurol.2010.10.002.

PMID:
21215918
15.

Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.

Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee.

Am J Respir Crit Care Med. 2010 Aug 1;182(3):298-306. doi: 10.1164/rccm.201002-0157CI.

PMID:
20675678
16.

Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts.

Stone A, Quittell L, Zhou J, Alba L, Bhat M, DeCelie-Germana J, Rajan S, Bonitz L, Welter JJ, Dozor AJ, Gherson I, Lowy FD, Saiman L.

Pediatr Infect Dis J. 2009 Oct;28(10):895-9.

PMID:
20135845
17.

Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives.

Marciel KK, Saiman L, Quittell LM, Dawkins K, Quittner AL.

Pediatr Pulmonol. 2010 Feb;45(2):157-64. doi: 10.1002/ppul.21164.

18.

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee.

Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3. Review.

PMID:
19729669
19.

Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis; North American Scientific Advisory Group for ESCF.

J Pediatr. 2009 Nov;155(5):634-9.e1-4. doi: 10.1016/j.jpeds.2009.04.059. Epub 2009 Jul 16.

20.

Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L.

Chest. 2009 Dec;136(6):1554-1560. doi: 10.1378/chest.09-0132. Epub 2009 Jun 8.

PMID:
19505987

Supplemental Content

Loading ...
Support Center